Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Innate Pharma SA Announces Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

07/06/2021 | 01:00am EDT

Innate Pharma SA announced that FORCE (FOR COVID-19 Elimination), the investigator-sponsored, Phase 2 clinical trial evaluating the safety and efficacy of its anti-C5aR1 antibody, avdoralimab, in COVID-19 patients with severe pneumonia, did not meet its primary endpoints in all three cohorts of the trial. The FORCE trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR1 pathway. These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care. Investigators and the Independent Data Monitoring Committee observed slightly higher deaths in the treatment arm compared to placebo without causality being established. Results from this trial, including translational data, are planned to be submitted for publication. Based on these results, the Company will stop exploring avdoralimab in COVID-19. This results do not impact the investigator-sponsored, Phase 2 trial of avdoralimab in bullous pemphigoid, an inflammatory disease, which is currently enrolling patients. More than 100 patients have been treated with avdoralimab in inflammation and oncology clinical trials with no new or unexpected safety signals observed.


© S&P Capital IQ 2021
All news about INNATE PHARMA
09/15GLOBAL MARKETS LIVE : Microsoft, Apple, The Boeing Company, AT&T, Activision Bli..
09/15INNATE PHARMA : REPORTS FIRST HALF 2021 FINANCIAL RESULTS AND BUSINESS UPDATE (F..
PU
09/15Innate Pharma Posts Wider H1 2021 Net Loss, Revenue Falls
MT
09/15INNATE PHARMA : Interim financial report 961.5 KB
PU
09/15INNATE PHARMA : Reports First Half 2021 Financial Results and Business Update
AQ
09/15Innate Pharma S.A. Announces Management Changes
CI
09/13NH TherAguix registration document approved by -2-
DJ
09/07Top Premarket Decliners
MT
09/07INNATE PHARMA S A : Top Brass to Offer H1 Business Update Next Week - Shares Dro..
MT
09/07INNATE PHARMA : Announces Conference Call and Webcast for First Half 2021 Busine..
PU
More news
Analyst Recommendations on INNATE PHARMA
More recommendations
Financials
Sales 2021 42,1 M 49,5 M 49,5 M
Net income 2021 -44,3 M -52,1 M -52,1 M
Net cash 2021 68,9 M 81,0 M 81,0 M
P/E ratio 2021 -8,28x
Yield 2021 -
Capitalization 374 M 440 M 439 M
EV / Sales 2021 7,25x
EV / Sales 2022 7,63x
Nbr of Employees 244
Free-Float 75,2%
Chart INNATE PHARMA
Duration : Period :
Innate Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INNATE PHARMA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 4,72 €
Average target price 5,90 €
Spread / Average Target 24,9%
EPS Revisions
Managers and Directors
Mondher Mahjoubi Chairman-Executive Board & Chief Executive Officer
Frederic Lombard Chief Financial Officer
Hervé Eloi Dominique Brailly Chairman-Supervisory Board
Eric Vivier Chief Scientific Officer & Senior Vice President
Odile Belzunce Senior VP-Compliance, IT & Operations
Sector and Competitors
1st jan.Capi. (M$)
INNATE PHARMA40.67%455
MODERNA, INC.315.87%175 368
LONZA GROUP AG34.92%61 973
IQVIA HOLDINGS INC.44.30%49 541
CELLTRION, INC.-25.63%31 848
SEAGEN INC.-13.16%27 670